Top

Published in:

Open Access 01-12-2023 | Chronic Obstructive Lung Disease | Review

Immunology in COPD and the use of combustible cigarettes and heated tobacco products

Authors: Justyna Błach, Mateusz Siedliński, Wojciech Sydor

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the most common chronic respiratory diseases, characterised by high morbidity and mortality. COPD is characterised by a progressive decline of lung function caused by chronic inflammatory reactions in the lung tissue due to continual exposure to harmful molecules by inhalation. As prevention plays a very important role in COPD, quitting smoking is the most important factor in reducing the decline in lung function. Unfortunately, many people are unable to break their nicotine addiction. This paper summarises current knowledge about combustible cigarettes (CSs) and alternative tobacco products such as heated tobacco products (HTPs) in COPD. The paper focuses on the immunological aspects of COPD and the influence of tobacco products on lung tissue immunology. There are differences in research results between HTPs and CSs in favour of HTPs. More long-term studies are needed to look at the effects of HTPs, especially in COPD. However, there is no doubt that it would be best for patients to give up their nicotine addiction completely.

Janjua S, Fortescue R, Poole P. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;5(5):CD002309. https://doi.org/10.1002/14651858.CD002309.pub6.CrossRefPubMed

Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389:1931–40.CrossRefPubMed

Terzikhan N, Verhamme KM, Hofman A, Stricker BH, Brusselle GG, Lahousse L. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. Eur J Epidemiol. 2016;31:785–92. https://doi.org/10.1007/s10654-016-0132-z.CrossRefPubMedPubMedCentral

Institute for Health Metrics and Evaluation (IHME) Findings from the Global Burden of Disease Study 2017: GBD Compare (Online). Seattle: Institute for Health Metrics and Evaluation (IHME) https://vizhub.healthdata.org/gbd-compare. Accessed 13 Oct 2019.

Kohansal R, Martinez-Camblor P, Agustí A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring cohort. Am J Respir Crit Care Med. 2009;180:3–10.CrossRefPubMed

Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–82.CrossRefPubMed

Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675–9.CrossRefPubMed

Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.CrossRefPubMed

Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J COPD. 2017;12:467–75.CrossRef

10.

Riesco JA, Alcázar B, Trigueros JA, Campuzano A, Pérez J, Lorenzo JL. Active smoking and COPD phenotype: distribution and impact on prognostic factors. Int J Chron Obstruct Pulmon Dis. 2017;12:1989–99.CrossRefPubMedPubMedCentral

11.

Miravitlles M, Barrecheguren M, Romaín-Rodríguez M. Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2015;19(8):992–8.CrossRefPubMed

12.

Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138:16–27.CrossRefPubMed

13.

Ramirez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med. 2014;190:996–1002.CrossRefPubMed

14.

Auer R, Concha-Lozano N, Jacot-Sadowski I, Cornuz J, Berthet A. Heat-not-burn tobacco cigarettes: smoke by any other name. JAMA Intern Med. 2017;177(7):1050–2.CrossRefPubMedPubMedCentral

15.

Baker R. Temperature distribution inside a burning cigarette. Nature. 1974;247:405–6. https://doi.org/10.1038/247405a0.CrossRef

16.

Bhat TA, Panzica L, Kalathil SG, Thanavala Y. Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015;12(Suppl 2):S169–75.CrossRefPubMedPubMedCentral

17.

Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18:454–66. https://doi.org/10.1038/s41577-018-0006-6.CrossRefPubMed

18.

Opitz B, van Laak V, Eitel J, Suttorp N. Innate immune recognition in infectious and noninfectious diseases of the lung. Am J Respir Crit Care Med. 2010;181:1294–309.CrossRefPubMed

19.

Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators Inflamm. 2013;2013: 413735.CrossRefPubMedPubMedCentral

20.

Decramer M, Janssens W, Miravitlles M. Chronic obstr uctive pulmonary disease. Lancet. 2012;379:1341–51.CrossRefPubMedPubMedCentral

21.

Birrell MA, Eltom S. The role of the NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol Ther. 2011;130:364–70.CrossRefPubMed

22.

Vitenberga Z, Pilmane M, Babjoniševa A. The evaluation of inflammatory, anti-inflammatory and regulatory factors contributing to the pathogenesis of COPD in airways. Pathol Res Pract. 2019;215(1):97–105.CrossRefPubMed

23.

Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31:1334–56.CrossRefPubMed

24.

Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010;363:2233–47.CrossRefPubMedPubMedCentral

25.

Silva MT. Macrophage phagocytosis of neutrophils at inflammatory/infectious foci: a cooperative mechanism in the control of infection and infectious inflammation. J Leukoc Biol. 2011;89:675–83.CrossRefPubMed

26.

Xu Y, Li H, Bajrami B, et al. Cigarette smoke (CS) and nicotine delay neutrophil spontaneous death via suppressing production of diphosphoinositol pentakisphosphate. Proc Natl Acad Sci U S A. 2013;110(19):7726–31. https://doi.org/10.1073/pnas.1302906110.CrossRefPubMedPubMedCentral

27.

Vlahos R, Bozinovski S. Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol. 2014;5:435.CrossRefPubMedPubMedCentral

28.

Lommatzsch M, Bratke K, Knappe T, et al. Acute effects of tobacco smoke on human airway dendritic cells in vivo. Eur Respir J. 2010;35:1130–6.CrossRefPubMed

29.

Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709–21.CrossRefPubMed

30.

Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, Capelli A, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol. 2009;157:316–24.CrossRefPubMedPubMedCentral

31.

Eriksson Ström J, Pourazar J, Linder R, Blomberg A, Lindberg A, Bucht A, et al. Cytotoxic lymphocytes in COPD airways: increased NK cells associated with disease, iNKT and NKT-like cells with current smoking. Respir Res. 2018;19(1):244.CrossRefPubMedPubMedCentral

32.

Caramori G, Ruggeri P, Di Stefano A, Mumby S, Girbino G, Adcock IM, et al. Autoimmunity and COPD: clinical implications. Chest. 2018;153:1424–31.CrossRefPubMed

33.

Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.CrossRefPubMed

34.

Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J. 2009;34:219–30.CrossRefPubMed

35.

Litsiou E, Semitekolou M, Galani IE, et al. CXCL13 production in B cells via Toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(11):1194–202.CrossRefPubMed

36.

Siedlinski M, Klanderman B, Sandhaus RA, et al. Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency. Epigenetics. 2012;7(7):720–8. https://doi.org/10.4161/epi.20319.CrossRefPubMedPubMedCentral

37.

Liu M, Jiang Y, Wedow R, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237–44. https://doi.org/10.1038/s41588-018-0307-5.CrossRefPubMedPubMedCentral

38.

Siedlinski M, Cho MH, Bakke P, COPDGene Investigators, ECLIPSE Investigators, et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax. 2011;66(10):894–902. https://doi.org/10.1136/thoraxjnl-2011-200154.CrossRefPubMed

39.

Shrine N, Guyatt AL, Erzurumluoglu AM, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet. 2019;51(3):481–93. https://doi.org/10.1038/s41588-018-0321-7.CrossRefPubMedPubMedCentral

40.

Faiz A, van den Berge M, Vermeulen CJ, Ten Hacken NHT, Guryev V, Pouwels SD. AGER expression and alternative splicing in bronchial biopsies of smokers and never smokers. Respir Res. 2019;20(1):70. https://doi.org/10.1186/s12931-019-1038-6.CrossRefPubMedPubMedCentral

41.

Faner R, Nuñez B, Sauleda J, et al. HLA distribution in COPD patients. COPD J Chron Obstruct Pulmon Dis. 2013;10(2):138–46. https://doi.org/10.3109/15412555.2012.729621.CrossRef

42.

Hobbs BD, Parker MM, Chen H, et al. Exome array analysis identifies a common variant in IL27 associated with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(1):48–57. https://doi.org/10.1164/rccm.201510-2053OC.CrossRefPubMedPubMedCentral

43.

Leigh NJ, Tran PL, O’Connor RJ, Goniewicz ML. Cytotoxic effects of heated tobacco products (HTP) on human bronchial epithelial cells. Tob Control. 2018;27(Suppl 1):s26–9. https://doi.org/10.1136/tobaccocontrol-2018-054317.CrossRefPubMed

44.

Daou MAZ, Shihadeh A, Hashem Y, et al. Role of diabetes in lung injury from acute exposure to electronic cigarette, heated tobacco product, and combustible cigarette aerosols in an animal model. PLoS ONE. 2021;16(8): e0255876. https://doi.org/10.1371/journal.pone.0255876.CrossRefPubMedPubMedCentral

45.

Bhat TA, Kalathil SG, Leigh N, et al. Acute effects of heated tobacco product (IQOS) aerosol inhalation on lung tissue damage and inflammatory changes in the lungs. Nicotine Tob Res. 2021;23(7):1160–7. https://doi.org/10.1093/ntr/ntaa267.CrossRefPubMed

46.

Wong ET, Luettich K, Krishnan S, Wong SK, et al. Reduced chronic toxicity and carcinogenicity in A/J mice in response to life-time exposure to aerosol from a heated tobacco product compared with cigarette smoke. Toxicol Sci. 2020;178(1):44–70. https://doi.org/10.1093/toxsci/kfaa131.CrossRefPubMedPubMedCentral

47.

Salman R, Talih S, El-Hage R, et al. Free-base and total nicotine, reactive oxygen species, and carbonyl emissions from IQOS, a heated tobacco product. Nicotine Tob Res. 2019;21(9):1285–8. https://doi.org/10.1093/ntr/nty235.CrossRefPubMed

48.

Malinska D, Szymański J, Patalas-Krawczyk P, Michalska B, Wojtala A, et al. Assessment of mitochondrial function following short- and long-term exposure of human bronchial epithelial cells to total particulate matter from a candidate modified-risk tobacco product and reference cigarettes. Food Chem Toxicol. 2018;115:1–12. https://doi.org/10.1016/j.fct.2018.02.013.CrossRefPubMed

49.

Sohal SS, Eapen MS, Naidu VGM, Sharma P. IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette. ERJ Open Res. 2019;5(1):00159–2018. https://doi.org/10.1183/23120541.00159-2018.CrossRefPubMedPubMedCentral

50.

Lee A, Lee SY, Lee KS. The use of heated tobacco products is associated with asthma, allergic rhinitis, and atopic dermatitis in Korean adolescents. Sci Rep. 2019;9(1):17699. https://doi.org/10.1038/s41598-019-54102-4.CrossRefPubMedPubMedCentral

51.

Aokage T, Tsukahara K, Fukuda Y, et al. Heat-not-burn cigarettes induce fulminant acute eosinophilic pneumonia requiring extracorporeal membrane oxygenation. Respir Med Case Rep. 2018;26:87–90. https://doi.org/10.1016/j.rmcr.2018.12.002.CrossRefPubMedPubMedCentral

52.

Kamada T, Yamashita Y, Tomioka H. Acute eosinophilic pneumonia following heat-not-burn cigarette smoking. Respirol Case Rep. 2016;4(6): e00190. https://doi.org/10.1002/rcr2.190.CrossRefPubMedPubMedCentral

53.

Li J, Tang R, Qiu H, Huang Q, Mason TG, Tian L. Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016;11(1):11–3079.

54.

Yang L, Li C, Tang X. The impact of PM2.5 on the host defense of respiratory system. Front Cell Dev Biol. 2020;8:91. https://doi.org/10.3389/fcell.2020.00091.CrossRefPubMedPubMedCentral

55.

He F, Liao B, Pu J, Li C, Zheng M, Huang L, Zhou Y, Zhao D, Li B, Ran P. Exposure to ambient particulate matter induced COPD in a rat model and a description of the underlying mechanism. Sci Rep. 2017;7:45666. https://doi.org/10.1038/srep45666.CrossRefPubMedPubMedCentral

56.

Migliaccio CT, Kobos E, King QO, Porter V, Jessop F, Ward T. Adverse effects of wood smoke PM2.5 exposure on macrophage functions. Inhal Toxicol. 2013;25:67–76. https://doi.org/10.3109/08958378.2012.756086.CrossRefPubMedPubMedCentral

57.

Sigaud S, Goldsmith CAW, Zhou H, Yang Z, Fedulov A, Imrich A, Kobzik L. Air pollution particles diminish bacterial clearance in the primed lungs of mice. Toxicol Appl Pharmacol. 2007;223:1–9. https://doi.org/10.1016/j.taap.2007.04.014.CrossRefPubMedPubMedCentral

58.

Zhao H, Li W, Gao Y, Li J, Wang H. Exposure to particular matter increases susceptibility to respiratory Staphylococcus aureus infection in rats via reducing pulmonary natural killer cells. Toxicology. 2014;325:180–8. https://doi.org/10.1016/j.tox.2014.09.006.CrossRefPubMed

59.

Chen X, Liu J, Zhou J, Wang J, Chen C, Song Y, Pan J. Urban particulate matter (PM) suppresses airway antibacterial defence. Respir Res. 2018;19:5. https://doi.org/10.1186/s12931-017-07000.CrossRefPubMedPubMedCentral

60.

Wang H, Song L, Ju W, et al. The acute airway inflammation induced by PM2.5 exposure and the treatment of essential oils in Balb/c mice. Sci Rep. 2017;7:44256. https://doi.org/10.1038/srep44256.CrossRefPubMedPubMedCentral

61.

Münzel T, Gori T, Al-Kindi S, et al. Effects of gaseous and solid constituents of air pollution on endothelial function. Eur Heart J. 2018;39:3543–50. https://doi.org/10.1093/eurheartj/ehy481.CrossRefPubMedPubMedCentral

62.

Peruzzi M, Cavarretta E, Frati G, et al. Comparative indoor pollution from Glo, Iqos, and Juul, using traditional combustion cigarettes as benchmark: evidence from the randomized SUR-VAPES AIR trial. Int J Environ Res Public Health. 2020;17(17):6029. https://doi.org/10.3390/ijerph17176029.CrossRefPubMedPubMedCentral

63.

Protano C, Manigrasso M, Cammalleri V, et al. Impact of electronic alternatives to tobacco cigarettes on indoor air particular matter levels. Int J Environ Res Public Health. 2020;17(8):2947. https://doi.org/10.3390/ijerph17082947.CrossRefPubMedPubMedCentral

64.

Talhout R, Schulz T, Florek E, van Benthem J, Wester P, Opperhuizen A. Hazardous compounds in tobacco smoke. Int J Env Res Pub Health. 2011;8(2):613–28.CrossRef

65.

Mallock N, Böss L, Burk R, Danziger M, Welsch T, Hahn H, Trieu HL, Hahn J, Pieper E, Henkler- Stephani F, et al. Levels of selected analytes in the emissions of “heat not burn” tobacco products that are relevant to assess human health risks. Arch Toxicol. 2018;92:2145–9. https://doi.org/10.1007/s00204-018-2215-y.CrossRefPubMedPubMedCentral

66.

Farsalinos KE, Yannovits N, Sarri T, Voudris V, Poulas K, Leischow SJ. Carbonyl emissions from a novel heated tobacco product (IQOS): comparison with an e-cigarette and a tobacco cigarette. Addiction. 2018;113:2099–106. https://doi.org/10.1111/add.14365.CrossRefPubMed

67.

Farsalinos KE, Yannovits N, Sarri T, Voudris V, Poulas K. Nicotine delivery to the aerosol of a heat-not-burn tobacco product: comparison with a tobacco cigarette and E-cigarettes. Nicotine Tob Res. 2018;20:1004–9. https://doi.org/10.1093/ntr/ntx138.CrossRefPubMed

68.

Dusautoir R, Zarcone G, Verriele M, Garçon G, Fronval I, et al. Comparison of the chemical composition of aerosols from heated tobacco products, electronic cigarettes and tobacco cigarettes and their toxic impacts on the human bronchial epithelial BEAS-2B cells. J Hazard Mater. 2021;401: 123417. https://doi.org/10.1016/j.jhazmat.2020.123417.CrossRefPubMed

69.

Polosa R, Morjaria JB, Prosperini U, et al. Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. Intern Emerg Med. 2021;16(3):687–96. https://doi.org/10.1007/s11739-021-02674-3.CrossRefPubMedPubMedCentral

70.

Lüdicke F, Ansari SM, Lama N, et al. Effects of switching to a heat-not-burn tobacco product on biologically relevant biomarkers to assess a candidate modified risk tobacco product: a randomized trial. Cancer Epidemiol Biomark Prev. 2019;28(11):1934–43. https://doi.org/10.1158/1055-9965.EPI-18-0915.CrossRef

71.

Akiyama Y, Sherwood N. Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. Toxicol Rep. 2021;8:282–94. https://doi.org/10.1016/j.toxrep.2021.01.014.CrossRefPubMedPubMedCentral

72.

Jimenez-Ruiz CA, Andreas S, Lewis KE, et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J. 2015;46:61–79.CrossRefPubMed

73.

Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010;65:711–8.CrossRefPubMed

74.

Tattan-Birch H, Hartmann-Boyce J, Kock L, Simonavicius E, Brose L, Jackson S, Shahab L, Brown J. Heated tobacco products for smoking cessation and reducing smoking prevalence. Cochrane Database Syst Rev. 2022;1(1):CD013790. https://doi.org/10.1002/14651858.CD013790.pub2.CrossRefPubMed

75.

Braznell S, Van Den Akker A, Metcalfe C, Taylor GM, Hartmann-Boyce J. Critical appraisal of interventional clinical trials assessing heated tobacco products: a systematic review. Tob Control. 2022. https://doi.org/10.1136/tc-2022-057522.CrossRefPubMed

Title: Immunology in COPD and the use of combustible cigarettes and heated tobacco products
Authors: Justyna Błach
Mateusz Siedliński
Wojciech Sydor
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Chronic Obstructive Lung Disease
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01374-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunology in COPD and the use of combustible cigarettes and heated tobacco products

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Gestational diabetes mellitus and its associated factors in Ethiopia: a systematic review and meta-analysis

Declined plasma microfibrillar-associated protein 4 levels in acute coronary syndrome

Comparison of clinical characteristics between adult-onset and juvenile-onset non-radiographic axial spondyloarthritis in Chinese patients: results from the COCAS cohort

Circadian rhythm in cardiovascular diseases: a bibliometric analysis of the past, present, and future

B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia

Dysregulated cholesterol regulatory genes in hepatocellular carcinoma